|
Jan 31
|
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
|
|
Dec 22
|
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
|
|
Dec 19
|
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
|
|
Dec 6
|
Outlook Therapeutics® Announces Strategic Organizational Realignment
|
|
Nov 28
|
Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term
|
|
Nov 27
|
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
|
|
Nov 2
|
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
|
|
Nov 1
|
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
|
|
Apr 27
|
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
|